Impax Laboratories, Inc. (IPXL) Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System trimmed its position in Impax Laboratories, Inc. (NASDAQ:IPXL) by 9.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 130,032 shares of the specialty pharmaceutical company’s stock after selling 14,244 shares during the period. California State Teachers Retirement System owned about 0.17% of Impax Laboratories worth $2,094,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Swiss National Bank lifted its stake in Impax Laboratories by 15.3% in the 2nd quarter. Swiss National Bank now owns 116,900 shares of the specialty pharmaceutical company’s stock worth $1,882,000 after purchasing an additional 15,500 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in Impax Laboratories by 3.2% in the 2nd quarter. Great West Life Assurance Co. Can now owns 106,856 shares of the specialty pharmaceutical company’s stock worth $1,715,000 after purchasing an additional 3,350 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in Impax Laboratories by 56.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 23,498 shares of the specialty pharmaceutical company’s stock worth $378,000 after purchasing an additional 8,469 shares in the last quarter. Vanguard Group Inc. lifted its stake in Impax Laboratories by 4.6% in the 1st quarter. Vanguard Group Inc. now owns 6,251,395 shares of the specialty pharmaceutical company’s stock worth $79,080,000 after purchasing an additional 276,765 shares in the last quarter. Finally, State of Wisconsin Investment Board lifted its stake in Impax Laboratories by 125.1% in the 2nd quarter. State of Wisconsin Investment Board now owns 280,616 shares of the specialty pharmaceutical company’s stock worth $4,518,000 after purchasing an additional 155,963 shares in the last quarter. Institutional investors own 88.32% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Impax Laboratories, Inc. (IPXL) Shares Sold by California State Teachers Retirement System” was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/11/15/impax-laboratories-inc-ipxl-shares-sold-by-california-state-teachers-retirement-system.html.

IPXL has been the topic of a number of research reports. BidaskClub lowered shares of Impax Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Cantor Fitzgerald reissued a “buy” rating and issued a $25.00 target price on shares of Impax Laboratories in a research note on Monday, September 25th. Royal Bank Of Canada set a $17.00 target price on shares of Impax Laboratories and gave the stock a “hold” rating in a research note on Thursday, August 10th. BTIG Research reissued a “buy” rating and issued a $27.00 target price (up from $20.00) on shares of Impax Laboratories in a research note on Saturday, September 23rd. Finally, Zacks Investment Research raised shares of Impax Laboratories from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Monday, October 16th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. Impax Laboratories currently has an average rating of “Hold” and a consensus price target of $19.60.

Shares of Impax Laboratories, Inc. (IPXL) opened at $17.17 on Wednesday. The stock has a market capitalization of $1,278.46, a P/E ratio of 25.37, a price-to-earnings-growth ratio of 1.09 and a beta of 0.99. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.81 and a quick ratio of 1.32. Impax Laboratories, Inc. has a 12-month low of $7.75 and a 12-month high of $25.70.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.03. The company had revenue of $206.40 million for the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. The firm’s quarterly revenue was down 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.37 earnings per share. equities research analysts expect that Impax Laboratories, Inc. will post 0.63 EPS for the current year.

Impax Laboratories Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Want to see what other hedge funds are holding IPXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Impax Laboratories, Inc. (NASDAQ:IPXL).

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply